Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group
Patients with follicular lymphoma (FL) and progression of disease (POD) within 24 months after frontline treatment (POD24) have poor overall survival (OS). The optimal salvage treatment for these patients is unknown. We assessed the role of high-dose therapy and autologous stem cell transplantation...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
29 March 2018
|
| In: |
Biology of blood and marrow transplantation
Year: 2018, Jahrgang: 24, Heft: 6, Pages: 1172-1179 |
| ISSN: | 1523-6536 |
| DOI: | 10.1016/j.bbmt.2018.03.022 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.bbmt.2018.03.022 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1083879118301563 
|
| Verfasserangaben: | Vindi Jurinovic, Bernd Metzner, Michael Pfreundschuh, Norbert Schmitz, Hannes Wandt, Ulrich Keller, Peter Dreger, Martin Dreyling, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Oliver Weigert |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1681090074 | ||
| 003 | DE-627 | ||
| 005 | 20230426153735.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191105s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bbmt.2018.03.022 |2 doi | |
| 035 | |a (DE-627)1681090074 | ||
| 035 | |a (DE-599)KXP1681090074 | ||
| 035 | |a (OCoLC)1341250426 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Jurinovic, Vindi |e VerfasserIn |0 (DE-588)1198903074 |0 (DE-627)1681089416 |4 aut | |
| 245 | 1 | 0 | |a Autologous stem cell transplantation for patients with early progression of follicular lymphoma |b a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group |c Vindi Jurinovic, Bernd Metzner, Michael Pfreundschuh, Norbert Schmitz, Hannes Wandt, Ulrich Keller, Peter Dreger, Martin Dreyling, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Oliver Weigert |
| 264 | 1 | |c 29 March 2018 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 05.11.2019 | ||
| 520 | |a Patients with follicular lymphoma (FL) and progression of disease (POD) within 24 months after frontline treatment (POD24) have poor overall survival (OS). The optimal salvage treatment for these patients is unknown. We assessed the role of high-dose therapy and autologous stem cell transplantation (ASCT) in transplant-eligible patients. We analyzed 162 patients with advanced-stage FL who had received frontline treatment within the GLSG1996 or GLSG2000 trials. All patients had POD at age ≤ 65 years and had not received a prior transplant. Second-line treatment was not specified by study protocols. Survival was calculated from time of second-line treatment. Eighteen patients (11%) progressed (n = 16) or died (n = 2) during cytoreductive second-line treatment (considered “cytoreduction failure”); none received ASCT, and their median second-line OS was <1 year. A total of 113 patients had POD24 (70%), whereas 49 had POD after 24 months (30%). Sixty-three patients without cytoreduction failure received ASCT (39%), and 81 received no transplant (50%). In patients with POD24, a significant survival benefit was associated with ASCT with a 5-year second-line progression-free survival for ASCT versus no transplant of 51% versus 19% (hazard ratio, .38; 95% confidence interval, .24 to .62; P < .0001) and a 5-year second-line OS of 77% versus 59% (hazard ratio, .54, 95% confidence interval, .30 to .95; P = .031). Thus, ASCT is an effective treatment option for transplant-eligible patients with high-risk FL as identified by POD24 and should be evaluated in prospective clinical trials. | ||
| 650 | 4 | |a Autologous stem cell transplantation | |
| 650 | 4 | |a Early progression of disease | |
| 650 | 4 | |a Follicular lymphoma | |
| 650 | 4 | |a Salvage treatment | |
| 650 | 4 | |a Transplant eligibility | |
| 700 | 1 | |a Metzner, Bernd |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pfreundschuh, Michael |d 1949-2018 |e VerfasserIn |0 (DE-588)108615871 |0 (DE-627)394701879 |0 (DE-576)289617227 |4 aut | |
| 700 | 1 | |a Schmitz, Norbert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wandt, Hannes |e VerfasserIn |0 (DE-588)1178026329 |0 (DE-627)1049109023 |0 (DE-576)517648636 |4 aut | |
| 700 | 1 | |a Keller, Ulrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 700 | 1 | |a Dreyling, Martin |d 1961- |e VerfasserIn |0 (DE-588)134015819 |0 (DE-627)559478143 |0 (DE-576)300256000 |4 aut | |
| 700 | 1 | |a Hiddemann, Wolfgang |d 1949- |e VerfasserIn |0 (DE-588)115582770 |0 (DE-627)077343220 |0 (DE-576)289961726 |4 aut | |
| 700 | 1 | |a Unterhalt, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hoster, Eva |d 1974- |e VerfasserIn |0 (DE-588)136888186 |0 (DE-627)588323861 |0 (DE-576)301330859 |4 aut | |
| 700 | 1 | |a Weigert, Oliver |d 1975- |e VerfasserIn |0 (DE-588)129555436 |0 (DE-627)472715453 |0 (DE-576)297720201 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biology of blood and marrow transplantation |d [Erscheinungsort nicht ermittelbar] : Elsevier Health Sciences, 1998 |g 24(2018), 6, Seite 1172-1179 |h Online-Ressource |w (DE-627)334374782 |w (DE-600)2057605-5 |w (DE-576)118352229 |x 1523-6536 |7 nnas |a Autologous stem cell transplantation for patients with early progression of follicular lymphoma a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group |
| 773 | 1 | 8 | |g volume:24 |g year:2018 |g number:6 |g pages:1172-1179 |g extent:8 |a Autologous stem cell transplantation for patients with early progression of follicular lymphoma a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.bbmt.2018.03.022 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1083879118301563 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20191105 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 999 | |a KXP-PPN1681090074 |e 3537438958 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title_sort":"Autologous stem cell transplantation for patients with early progression of follicular lymphoma","title":"Autologous stem cell transplantation for patients with early progression of follicular lymphoma","subtitle":"a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group"}],"recId":"1681090074","origin":[{"dateIssuedDisp":" 29 March 2018","dateIssuedKey":"2018"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 05.11.2019"],"relHost":[{"pubHistory":["Volume 4, issue 1 (June 1998)-Volume 26, issue 12 (December 2020)"],"part":{"year":"2018","text":"24(2018), 6, Seite 1172-1179","volume":"24","extent":"8","pages":"1172-1179","issue":"6"},"language":["eng"],"title":[{"subtitle":"BBMT ; the official journal of the American Society for Blood and Marrow Transplantation","title":"Biology of blood and marrow transplantation","title_sort":"Biology of blood and marrow transplantation"}],"origin":[{"publisher":"Elsevier Health Sciences ; Carden Jennings","dateIssuedDisp":"[1998-2020]","publisherPlace":"[Erscheinungsort nicht ermittelbar] ; Charlottesville, Va."}],"recId":"334374782","type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"BBMT"}],"note":["Gesehen am 16.03.2021"],"id":{"issn":["1523-6536"],"zdb":["2057605-5"],"eki":["334374782"]},"disp":"Autologous stem cell transplantation for patients with early progression of follicular lymphoma a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study GroupBiology of blood and marrow transplantation","physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"8 S."}],"id":{"doi":["10.1016/j.bbmt.2018.03.022"],"eki":["1681090074"]},"name":{"displayForm":["Vindi Jurinovic, Bernd Metzner, Michael Pfreundschuh, Norbert Schmitz, Hannes Wandt, Ulrich Keller, Peter Dreger, Martin Dreyling, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Oliver Weigert"]},"person":[{"family":"Jurinovic","display":"Jurinovic, Vindi","role":"aut","given":"Vindi"},{"display":"Metzner, Bernd","given":"Bernd","role":"aut","family":"Metzner"},{"family":"Pfreundschuh","display":"Pfreundschuh, Michael","given":"Michael","role":"aut"},{"family":"Schmitz","role":"aut","given":"Norbert","display":"Schmitz, Norbert"},{"family":"Wandt","given":"Hannes","role":"aut","display":"Wandt, Hannes"},{"family":"Keller","display":"Keller, Ulrich","given":"Ulrich","role":"aut"},{"family":"Dreger","given":"Peter","role":"aut","display":"Dreger, Peter"},{"role":"aut","given":"Martin","display":"Dreyling, Martin","family":"Dreyling"},{"family":"Hiddemann","given":"Wolfgang","role":"aut","display":"Hiddemann, Wolfgang"},{"role":"aut","given":"Michael","display":"Unterhalt, Michael","family":"Unterhalt"},{"family":"Hoster","display":"Hoster, Eva","given":"Eva","role":"aut"},{"given":"Oliver","role":"aut","display":"Weigert, Oliver","family":"Weigert"}]} | ||
| SRT | |a JURINOVICVAUTOLOGOUS2920 | ||